Atorvastatin in Pulmonary Arterial Hypertension (APATH) study
Statins have been shown to both prevent and attenuate pulmonary hypertension in animal models. This study investigates the potential therapeutic benefits of atorvastatin as an affordable treatment for pulmonary hypertension patients. 220 patients with pulmonary arterial hypertension (PAH) or chronic...
Gespeichert in:
| Veröffentlicht in: | The European respiratory journal 2012-07, Vol.40 (1), p.67-74 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 74 |
|---|---|
| container_issue | 1 |
| container_start_page | 67 |
| container_title | The European respiratory journal |
| container_volume | 40 |
| creator | ZENG, Wei-Jie XIONG, Chang-Ming WILKINS, Martin R HE, Jian-Guo LAN ZHAO SHAN, Guang-Liang LIU, Zhi-Hong FANG XUE QING GU NI, Xin-Hai ZHAO, Zhi-Hui CHENG, Xian-Sheng |
| description | Statins have been shown to both prevent and attenuate pulmonary hypertension in animal models. This study investigates the potential therapeutic benefits of atorvastatin as an affordable treatment for pulmonary hypertension patients. 220 patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) were randomised, double-blind, to receive atrovastatin 10 mg daily or matching placebo in addition to supportive care. At 6 months, 6-min walk distance decreased by 16.6 m in the atorvastatin group and 14.1 m in the placebo group. The mean placebo-corrected treatment effect was -2.5 m (95% CI: -38-33; p=0.96), based on intention to treat. A small nonsignificant increase in pulmonary vascular resistance and fall in cardiac output was seen in both treatment groups. There was no significant difference in the proportion of patients who improved, remained stable or showed a deterioration in World Health Organization functional class between atorvastatin and placebo treatments. Nine patients died in the atorvastatin group and 11 in the placebo group. Serum cholesterol levels fell significantly on atorvastatin treatment. Discontinuation rates were 23.2% and 26.9% on atorvastatin and placebo, respectively. Atorvastatin 10 mg daily has no beneficial effect on the natural history of PAH or CTEPH over 6 months. |
| doi_str_mv | 10.1183/09031936.00149011 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1037241689</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1037241689</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-4d1348e0d752d7be91bd412914e085f062c6de82c0c085c47d33f6b3d17a3c2b3</originalsourceid><addsrcrecordid>eNpFkE1LAzEQQIMotlZ_gBfZi1APWzOZNLs5eFiKWqFgD_W8ZJMsrOxHTXaF_vumtFUYmBnmzcA8Qu6BzgBSfKaSIkgUM0qBSwpwQcaAUsZIKV6S8WEeH4ARufH-O1CCI1yTEWMoWMrFmLxkfed-le9VX7VRiPVQN12r3C7KXG9dpepoudvaULe-6tpomq2zzfIp8v1gdrfkqlS1t3enPCFfb6-bxTJefb5_LLJVrDmnfcwNIE8tNcmcmaSwEgrDgUnglqbzkgqmhbEp01SHXvPEIJaiQAOJQs0KnJDp8e7WdT-D9X3eVF7bulat7QafA8WEcRCpDCgcUe06750t862rmvBPgPKDtfxsLT9bCzsPp_ND0Vjzt3HWFIDHE6C8VnXpVKsr_8-JYFYkEve0LHJW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1037241689</pqid></control><display><type>article</type><title>Atorvastatin in Pulmonary Arterial Hypertension (APATH) study</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>ZENG, Wei-Jie ; XIONG, Chang-Ming ; WILKINS, Martin R ; HE, Jian-Guo ; LAN ZHAO ; SHAN, Guang-Liang ; LIU, Zhi-Hong ; FANG XUE ; QING GU ; NI, Xin-Hai ; ZHAO, Zhi-Hui ; CHENG, Xian-Sheng</creator><creatorcontrib>ZENG, Wei-Jie ; XIONG, Chang-Ming ; WILKINS, Martin R ; HE, Jian-Guo ; LAN ZHAO ; SHAN, Guang-Liang ; LIU, Zhi-Hong ; FANG XUE ; QING GU ; NI, Xin-Hai ; ZHAO, Zhi-Hui ; CHENG, Xian-Sheng ; Atorvastatin in Pulmonary Arterial Hypertension (APATH) Study Group</creatorcontrib><description>Statins have been shown to both prevent and attenuate pulmonary hypertension in animal models. This study investigates the potential therapeutic benefits of atorvastatin as an affordable treatment for pulmonary hypertension patients. 220 patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) were randomised, double-blind, to receive atrovastatin 10 mg daily or matching placebo in addition to supportive care. At 6 months, 6-min walk distance decreased by 16.6 m in the atorvastatin group and 14.1 m in the placebo group. The mean placebo-corrected treatment effect was -2.5 m (95% CI: -38-33; p=0.96), based on intention to treat. A small nonsignificant increase in pulmonary vascular resistance and fall in cardiac output was seen in both treatment groups. There was no significant difference in the proportion of patients who improved, remained stable or showed a deterioration in World Health Organization functional class between atorvastatin and placebo treatments. Nine patients died in the atorvastatin group and 11 in the placebo group. Serum cholesterol levels fell significantly on atorvastatin treatment. Discontinuation rates were 23.2% and 26.9% on atorvastatin and placebo, respectively. Atorvastatin 10 mg daily has no beneficial effect on the natural history of PAH or CTEPH over 6 months.</description><identifier>ISSN: 0903-1936</identifier><identifier>EISSN: 1399-3003</identifier><identifier>DOI: 10.1183/09031936.00149011</identifier><identifier>PMID: 22362846</identifier><language>eng</language><publisher>Leeds: Maney</publisher><subject>Adolescent ; Adult ; Aged ; Anticholesteremic Agents - therapeutic use ; Arterial hypertension. Arterial hypotension ; Atorvastatin ; Biological and medical sciences ; Blood and lymphatic vessels ; Cardiology. Vascular system ; Cholesterol, LDL ; Double-Blind Method ; Exercise Tolerance - drug effects ; Familial Primary Pulmonary Hypertension ; Female ; Hemodynamics ; Heptanoic Acids - therapeutic use ; Humans ; Hypertension, Pulmonary - drug therapy ; Hypertension, Pulmonary - mortality ; Lung - drug effects ; Lung - physiopathology ; Male ; Medical sciences ; Middle Aged ; Pneumology ; Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases ; Pyrroles - therapeutic use ; Treatment Outcome ; Walking ; Young Adult</subject><ispartof>The European respiratory journal, 2012-07, Vol.40 (1), p.67-74</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-4d1348e0d752d7be91bd412914e085f062c6de82c0c085c47d33f6b3d17a3c2b3</citedby><cites>FETCH-LOGICAL-c440t-4d1348e0d752d7be91bd412914e085f062c6de82c0c085c47d33f6b3d17a3c2b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26016679$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22362846$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ZENG, Wei-Jie</creatorcontrib><creatorcontrib>XIONG, Chang-Ming</creatorcontrib><creatorcontrib>WILKINS, Martin R</creatorcontrib><creatorcontrib>HE, Jian-Guo</creatorcontrib><creatorcontrib>LAN ZHAO</creatorcontrib><creatorcontrib>SHAN, Guang-Liang</creatorcontrib><creatorcontrib>LIU, Zhi-Hong</creatorcontrib><creatorcontrib>FANG XUE</creatorcontrib><creatorcontrib>QING GU</creatorcontrib><creatorcontrib>NI, Xin-Hai</creatorcontrib><creatorcontrib>ZHAO, Zhi-Hui</creatorcontrib><creatorcontrib>CHENG, Xian-Sheng</creatorcontrib><creatorcontrib>Atorvastatin in Pulmonary Arterial Hypertension (APATH) Study Group</creatorcontrib><title>Atorvastatin in Pulmonary Arterial Hypertension (APATH) study</title><title>The European respiratory journal</title><addtitle>Eur Respir J</addtitle><description>Statins have been shown to both prevent and attenuate pulmonary hypertension in animal models. This study investigates the potential therapeutic benefits of atorvastatin as an affordable treatment for pulmonary hypertension patients. 220 patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) were randomised, double-blind, to receive atrovastatin 10 mg daily or matching placebo in addition to supportive care. At 6 months, 6-min walk distance decreased by 16.6 m in the atorvastatin group and 14.1 m in the placebo group. The mean placebo-corrected treatment effect was -2.5 m (95% CI: -38-33; p=0.96), based on intention to treat. A small nonsignificant increase in pulmonary vascular resistance and fall in cardiac output was seen in both treatment groups. There was no significant difference in the proportion of patients who improved, remained stable or showed a deterioration in World Health Organization functional class between atorvastatin and placebo treatments. Nine patients died in the atorvastatin group and 11 in the placebo group. Serum cholesterol levels fell significantly on atorvastatin treatment. Discontinuation rates were 23.2% and 26.9% on atorvastatin and placebo, respectively. Atorvastatin 10 mg daily has no beneficial effect on the natural history of PAH or CTEPH over 6 months.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Anticholesteremic Agents - therapeutic use</subject><subject>Arterial hypertension. Arterial hypotension</subject><subject>Atorvastatin</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Cardiology. Vascular system</subject><subject>Cholesterol, LDL</subject><subject>Double-Blind Method</subject><subject>Exercise Tolerance - drug effects</subject><subject>Familial Primary Pulmonary Hypertension</subject><subject>Female</subject><subject>Hemodynamics</subject><subject>Heptanoic Acids - therapeutic use</subject><subject>Humans</subject><subject>Hypertension, Pulmonary - drug therapy</subject><subject>Hypertension, Pulmonary - mortality</subject><subject>Lung - drug effects</subject><subject>Lung - physiopathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pneumology</subject><subject>Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases</subject><subject>Pyrroles - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Walking</subject><subject>Young Adult</subject><issn>0903-1936</issn><issn>1399-3003</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1LAzEQQIMotlZ_gBfZi1APWzOZNLs5eFiKWqFgD_W8ZJMsrOxHTXaF_vumtFUYmBnmzcA8Qu6BzgBSfKaSIkgUM0qBSwpwQcaAUsZIKV6S8WEeH4ARufH-O1CCI1yTEWMoWMrFmLxkfed-le9VX7VRiPVQN12r3C7KXG9dpepoudvaULe-6tpomq2zzfIp8v1gdrfkqlS1t3enPCFfb6-bxTJefb5_LLJVrDmnfcwNIE8tNcmcmaSwEgrDgUnglqbzkgqmhbEp01SHXvPEIJaiQAOJQs0KnJDp8e7WdT-D9X3eVF7bulat7QafA8WEcRCpDCgcUe06750t862rmvBPgPKDtfxsLT9bCzsPp_ND0Vjzt3HWFIDHE6C8VnXpVKsr_8-JYFYkEve0LHJW</recordid><startdate>20120701</startdate><enddate>20120701</enddate><creator>ZENG, Wei-Jie</creator><creator>XIONG, Chang-Ming</creator><creator>WILKINS, Martin R</creator><creator>HE, Jian-Guo</creator><creator>LAN ZHAO</creator><creator>SHAN, Guang-Liang</creator><creator>LIU, Zhi-Hong</creator><creator>FANG XUE</creator><creator>QING GU</creator><creator>NI, Xin-Hai</creator><creator>ZHAO, Zhi-Hui</creator><creator>CHENG, Xian-Sheng</creator><general>Maney</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120701</creationdate><title>Atorvastatin in Pulmonary Arterial Hypertension (APATH) study</title><author>ZENG, Wei-Jie ; XIONG, Chang-Ming ; WILKINS, Martin R ; HE, Jian-Guo ; LAN ZHAO ; SHAN, Guang-Liang ; LIU, Zhi-Hong ; FANG XUE ; QING GU ; NI, Xin-Hai ; ZHAO, Zhi-Hui ; CHENG, Xian-Sheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-4d1348e0d752d7be91bd412914e085f062c6de82c0c085c47d33f6b3d17a3c2b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Anticholesteremic Agents - therapeutic use</topic><topic>Arterial hypertension. Arterial hypotension</topic><topic>Atorvastatin</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Cardiology. Vascular system</topic><topic>Cholesterol, LDL</topic><topic>Double-Blind Method</topic><topic>Exercise Tolerance - drug effects</topic><topic>Familial Primary Pulmonary Hypertension</topic><topic>Female</topic><topic>Hemodynamics</topic><topic>Heptanoic Acids - therapeutic use</topic><topic>Humans</topic><topic>Hypertension, Pulmonary - drug therapy</topic><topic>Hypertension, Pulmonary - mortality</topic><topic>Lung - drug effects</topic><topic>Lung - physiopathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pneumology</topic><topic>Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases</topic><topic>Pyrroles - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Walking</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ZENG, Wei-Jie</creatorcontrib><creatorcontrib>XIONG, Chang-Ming</creatorcontrib><creatorcontrib>WILKINS, Martin R</creatorcontrib><creatorcontrib>HE, Jian-Guo</creatorcontrib><creatorcontrib>LAN ZHAO</creatorcontrib><creatorcontrib>SHAN, Guang-Liang</creatorcontrib><creatorcontrib>LIU, Zhi-Hong</creatorcontrib><creatorcontrib>FANG XUE</creatorcontrib><creatorcontrib>QING GU</creatorcontrib><creatorcontrib>NI, Xin-Hai</creatorcontrib><creatorcontrib>ZHAO, Zhi-Hui</creatorcontrib><creatorcontrib>CHENG, Xian-Sheng</creatorcontrib><creatorcontrib>Atorvastatin in Pulmonary Arterial Hypertension (APATH) Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The European respiratory journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ZENG, Wei-Jie</au><au>XIONG, Chang-Ming</au><au>WILKINS, Martin R</au><au>HE, Jian-Guo</au><au>LAN ZHAO</au><au>SHAN, Guang-Liang</au><au>LIU, Zhi-Hong</au><au>FANG XUE</au><au>QING GU</au><au>NI, Xin-Hai</au><au>ZHAO, Zhi-Hui</au><au>CHENG, Xian-Sheng</au><aucorp>Atorvastatin in Pulmonary Arterial Hypertension (APATH) Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Atorvastatin in Pulmonary Arterial Hypertension (APATH) study</atitle><jtitle>The European respiratory journal</jtitle><addtitle>Eur Respir J</addtitle><date>2012-07-01</date><risdate>2012</risdate><volume>40</volume><issue>1</issue><spage>67</spage><epage>74</epage><pages>67-74</pages><issn>0903-1936</issn><eissn>1399-3003</eissn><abstract>Statins have been shown to both prevent and attenuate pulmonary hypertension in animal models. This study investigates the potential therapeutic benefits of atorvastatin as an affordable treatment for pulmonary hypertension patients. 220 patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) were randomised, double-blind, to receive atrovastatin 10 mg daily or matching placebo in addition to supportive care. At 6 months, 6-min walk distance decreased by 16.6 m in the atorvastatin group and 14.1 m in the placebo group. The mean placebo-corrected treatment effect was -2.5 m (95% CI: -38-33; p=0.96), based on intention to treat. A small nonsignificant increase in pulmonary vascular resistance and fall in cardiac output was seen in both treatment groups. There was no significant difference in the proportion of patients who improved, remained stable or showed a deterioration in World Health Organization functional class between atorvastatin and placebo treatments. Nine patients died in the atorvastatin group and 11 in the placebo group. Serum cholesterol levels fell significantly on atorvastatin treatment. Discontinuation rates were 23.2% and 26.9% on atorvastatin and placebo, respectively. Atorvastatin 10 mg daily has no beneficial effect on the natural history of PAH or CTEPH over 6 months.</abstract><cop>Leeds</cop><pub>Maney</pub><pmid>22362846</pmid><doi>10.1183/09031936.00149011</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0903-1936 |
| ispartof | The European respiratory journal, 2012-07, Vol.40 (1), p.67-74 |
| issn | 0903-1936 1399-3003 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1037241689 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adolescent Adult Aged Anticholesteremic Agents - therapeutic use Arterial hypertension. Arterial hypotension Atorvastatin Biological and medical sciences Blood and lymphatic vessels Cardiology. Vascular system Cholesterol, LDL Double-Blind Method Exercise Tolerance - drug effects Familial Primary Pulmonary Hypertension Female Hemodynamics Heptanoic Acids - therapeutic use Humans Hypertension, Pulmonary - drug therapy Hypertension, Pulmonary - mortality Lung - drug effects Lung - physiopathology Male Medical sciences Middle Aged Pneumology Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases Pyrroles - therapeutic use Treatment Outcome Walking Young Adult |
| title | Atorvastatin in Pulmonary Arterial Hypertension (APATH) study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T23%3A14%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Atorvastatin%20in%20Pulmonary%20Arterial%20Hypertension%20(APATH)%20study&rft.jtitle=The%20European%20respiratory%20journal&rft.au=ZENG,%20Wei-Jie&rft.aucorp=Atorvastatin%20in%20Pulmonary%20Arterial%20Hypertension%20(APATH)%20Study%20Group&rft.date=2012-07-01&rft.volume=40&rft.issue=1&rft.spage=67&rft.epage=74&rft.pages=67-74&rft.issn=0903-1936&rft.eissn=1399-3003&rft_id=info:doi/10.1183/09031936.00149011&rft_dat=%3Cproquest_cross%3E1037241689%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1037241689&rft_id=info:pmid/22362846&rfr_iscdi=true |